Chemotherapy for the treatment of alveolar echinococcosis: Where are we?
Parasite · 2024
DOI: 10.1051/parasite/2024055 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Parasite, 2024. Verfasst von Brice Autier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France. Hauptthemen laut MEDLINE: Echinococcosis, Echinococcus multilocularis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Alveolar echinococcosis (AE) is a severe liver disease due to infection with the Echinococcus multilocularis larval stage, called the metacestode. Management of AE is based on benzimidazole chemotherapy (albendazole or mebendazole), associated with surgery when possible. Benzimidazoles are the only compounds recommended for the treatment of AE; however, these are parasitostatic, which means that the parasite can resume growth when treatment is interrupted. Also, benzimidazoles can cause liver dysfunction which may prevent their use. Numerous drugs have been reported to have in vitro activity against E. multilocularis , but few had satisfactory in vivo activity, and none were clearly more effective than benzimidazoles. These drugs belong to various therapeutic categories including anti-infective agents ( e.g. amphotericin B, mefloquine, pentamidine derivatives), anti-neoplastic compounds ( e.g. imatinib, nilotinib, bortezomib), plant-extracted compounds ( e.g. thymol, crocin, carvacrol) and others ( e.g. metformin, verapamil, thiaclopride). These treatments are generally of limited interest due to their toxicity, their unfavorable pharmacokinetics, or the scarcity of studies involving humans. Apart from benzimidazoles, only amphotericin B, mefloquine and nitazoxanide have been reported to be used for human AE treatment, with unsatisfactory results. Few studies have aimed at developing innovative strategies for AE drug therapy, such as vectorization of drugs using nanoparticles. Altogether, this review emphasizes the urgent need for new therapeutic strategies in AE management, for which there is currently no curative chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
- Université de Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
ORCID-Profile: Brice Autier, Florence Robert-Gangneux, Sarah Dion
Zitieren
APA
Autier, B., Robert-Gangneux, F., & Dion, S. (2024). Chemotherapy for the treatment of alveolar echinococcosis: Where are we?. Parasite. https://doi.org/10.1051/parasite/2024055
Vancouver
Autier B, Robert-Gangneux F, Dion S. Chemotherapy for the treatment of alveolar echinococcosis: Where are we?. Parasite. 2024. doi:10.1051/parasite/2024055
BibTeX
@article{Autier2024,
author = {Autier, Brice and Robert-Gangneux, Florence and Dion, Sarah},
title = {Chemotherapy for the treatment of alveolar echinococcosis: Where are we?},
journal = {Parasite},
year = {2024},
doi = {10.1051/parasite/2024055}
}
EUVIMED